Catalio Capital Management, LP
Long book
$478.7M
Q1 2026
Positions
41
Top-10 weight
54%
concentration
Last quarter
+24.6%
SPY +14.8%
Turnover
44%
of book per quarter
Strategy in plain words
auto-generated from filingsCatalio Capital Management, LP is a concentrated fundamental stock-picker, specialised in healthcare (95% of the long book), running a $478.7M US long book across 41 positions.
The portfolio is concentrated: the top 10 names carry 54% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: DIANTHUS THERAPEUTICS INC, BRIDGEBIO PHARMA INC, The Bank of New York Mellon Corporation, BRISTOL-MYERS SQUIBB CO, SYNDAX PHARMACEUTICALS INC.
Over the last 6 quarters its long book ran on average 4.4pp per quarter ahead of the S&P 500, beating the index in 3 of 6 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-12.1%
Q1 2025
+1.2%
Q2 2025
+19.8%
Q3 2025
+26.2%
Q4 2025
-5.3%
Q1 2026
+24.6%
Sector allocation
Healthcare 84%
Other 12%
Materials 5%
Long book by quarter
What does Catalio Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 560.3K | $47.0M | 9.8% | -14.3% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 432.0K | $32.1M | 6.7% | New |
| BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 420.7K | $25.5M | 5.3% | -35.1% |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.0M | $24.4M | 5.1% | -12.8% |
| GILD GILEAD SCIENCES INC | Healthcare | 163.9K | $22.8M | 4.8% | -43.3% |
| 430 TERNS PHARMACEUTICALS INC | — | 409.0K | $21.6M | 4.5% | +198.7% |
| DFTX DEFINIUM THERAPEUTICS INC | Materials | 1.0M | $19.6M | 4.1% | New |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 577.8K | $19.3M | 4.0% | +60.4% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 299.3K | $18.8M | 3.9% | -17.0% |
| RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 850.8K | $17.8M | 3.7% | +423.4% |
| INCY INCYTE CORP | Healthcare | 182.1K | $17.1M | 3.6% | New |
| CYTK CYTOKINETICS INC | Healthcare | 215.5K | $14.2M | 3.0% | -16.6% |
| NTRA NATERA INC | Healthcare | 70.9K | $14.2M | 3.0% | +13.9% |
| CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 891.9K | $13.0M | 2.7% | New |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 439.0K | $11.9M | 2.5% | +32.3% |
| EW EDWARDS LIFESCIENCES CORP | Healthcare | 144.6K | $11.6M | 2.4% | -22.7% |
| MANE VERADERMICS INC | Healthcare | 173.6K | $11.0M | 2.3% | New |
| ADPT ADAPTIVE BIOTECHNOLOGIES | Healthcare | 722.8K | $10.0M | 2.1% | -12.0% |
| HTFL HEARTFLOW INC | Healthcare | 403.6K | $9.8M | 2.1% | +254.5% |
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 426.6K | $8.6M | 1.8% | New |
| QURE UNIQURE NV | Healthcare | 491.1K | $8.0M | 1.7% | +70.3% |
| IRON DISC MEDICINE INC | Healthcare | 123.0K | $7.9M | 1.6% | +11.4% |
| SEPN SEPTERNA INC | Healthcare | 294.4K | $7.1M | 1.5% | Held |
| DYN DYNE THERAPEUTICS INC | Healthcare | 283.0K | $5.1M | 1.1% | -45.6% |
| ELDN ELEDON PHARMACEUTICALS INC | Healthcare | 1.6M | $5.1M | 1.1% | +30.2% |
| KPTI KARYOPHARM THERAPEUTICS INC | Healthcare | 897.7K | $5.0M | 1.0% | +527.8% |
| SUPN SUPERNUS PHARMACEUTICALS INC | Healthcare | 62.0K | $3.2M | 0.7% | -75.9% |
| TARA PROTARA THERAPEUTIC INC | Healthcare | 580.0K | $3.0M | 0.6% | -59.9% |
| PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 247.8K | $2.8M | 0.6% | -64.6% |
| NAMS NEWAMSTERDAM PHARMA CO NV | Healthcare | 83.6K | $2.7M | 0.6% | New |
| TYRA TYRA BIOSCIENCES INC | Healthcare | 67.3K | $2.6M | 0.5% | New |
| GUTS FRACTYL HEALTH INC | Healthcare | 5.5M | $2.5M | 0.5% | Held |
| HYPR HYPERFINE INC | Healthcare | 1.3M | $1.4M | 0.3% | Held |
| MGX METAGENOMI THERAPEUTICS INC | Healthcare | 529.0K | $709K | 0.1% | Held |
| ATAI ATAIBECKLEY INC | Healthcare | 196.9K | $697K | 0.1% | New |
| FTH FAETH THERAPEUTICS INC | Healthcare | 14.7K | $464K | 0.1% | Held |
| OM OUTSET MEDICAL INC | Healthcare | 118.3K | $454K | 0.1% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 41 | $478.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 45 | $565.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 38 | $540.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 40 | $476.9M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 37 | $411.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 33 | $457.1M | canonical | SEC ↗ |